Notes from the Field: Amphetamine Use Among Workers with Severe Hyperthermia — Eight States, 2010–2019
Weekly / July 31, 2020 / 69(30);1004–1005
Andrew S. Karasick, MD1,2; Richard J. Thomas, MD1; Dawn L. Cannon, MD1; Kathleen M. Fagan, MD1; Patricia A. Bray, MD1; Michael J. Hodgson, MD1; Aaron W. Tustin, MD1 (View author affiliations)View suggested citation
Views equals page views plus PDF downloads
Workers can develop hyperthermia when core body temperature rises because of heat stress (environmental heat plus metabolic heat from physical activity) (1). Amphetamines are central nervous system stimulants that can induce hyperthermia independently or in combination with other risk factors (2). During 2010–2016, the Directorate of Technical Support and Emergency Management’s Office of Occupational Medicine and Nursing (OOMN), at the Occupational Safety and Health Administration (OSHA), identified three workers with fatal hyperthermia who tested positive for methamphetamine (3). To identify additional cases of severe hyperthermia in which workers tested positive for amphetamines, and to support OSHA’s enforcement activities, OOMN reviewed all medical records and investigation materials submitted by other OSHA offices to OOMN during January 1, 2010–August 31, 2019. OSHA field offices obtained the records from employers and health care facilities as part of OSHA’s inspections to enforce occupational safety and health regulations. Confirmed severe hyperthermia was defined as highly elevated body temperature (e.g., core temperature ≥104°F [40°C] or peripheral temperature ≥102°F [38.9°C]) associated with death or serious central nervous system dysfunction (e.g., coma or seizure). For out-of-hospital deaths with no body temperature measurement, suspected severe hyperthermia was defined as a determination by a medical examiner or other responsible postmortem investigator that hyperthermia caused or contributed to the death. The record review identified 111 heat-related illnesses, 46 of which involved severe hyperthermia (38 fatal and eight nonfatal illnesses).
Toxicology results (e.g., urine drug screens or postmortem blood tests) were available in 34 (73.9%) of the 46 cases of severe hyperthermia (including the three previously mentioned methamphetamine cases). Nine (26.5%) of these 34 workers tested positive for an amphetamine-class substance.* All nine were adult males aged 18–47 years (median = 30 years) working in various industrial settings in eight U.S. states† on warm days in summer or late spring (Table). Based on data from the nearest National Weather Service observation stations, the maximum outdoor heat index (a metric that combines temperature and relative humidity into a single number that represents how hot the conditions feel to humans) ranged from 86°F to 107°F (median = 97°F) on the days of the nine incidents.
Seven of the nine workers died, and two survived life-threatening illnesses. Peak body temperature ranged from 103°F to 110.6°F (39.4°C to 43.7°C) in eight workers with confirmed severe hyperthermia. In one fatality with no premortem body temperature measurement, the medical examiner suspected that hyperthermia was a significant contributing condition, based upon the circumstances (i.e., death occurred in a hot environment after strenuous activity on a hot day) and lack of anatomic evidence of an alternative cause of death (e.g., myocardial infarction).
According to medical records and medical examiner reports obtained by OSHA, illicit amphetamine use appeared to be present in seven cases; three postmortem blood assays detected methamphetamine, and four qualitative screening tests detected amphetamine or amphetamine analogs in workers without amphetamine prescriptions. One of the latter four workers died of hyperthermia on his first day at a new job, after reportedly receiving a drug from his supervisor. In that case, a coworker later alleged to OSHA that before the shift started, the supervisor had provided pills whose appearance was consistent with those of a prescription amphetamine. Two cases involved legal use of prescription amphetamines to treat attention deficit hyperactivity disorder, and both persons who used legal prescription amphetamines died. Co-occurring substances detected by blood or urine toxicology testing included tetrahydrocannabinol (four patients), benzodiazepines (two), opioids (one), tricyclic antidepressants (one), antihistamines (one), and caffeine (one). Clinicians and investigators determined that these co-occurring substances were not causally related to the hyperthermia outcomes.
This investigation revealed a high prevalence (>25%) of amphetamine use among 34 workers with severe hyperthermia. CDC’s National Institute for Occupational Safety and Health (NIOSH) has found that amphetamines are associated with heat intolerance (1), but reports of workplace hyperthermia where amphetamines were detected are limited (4). Workers and supervisors should be aware of potential hyperthermia-inducing synergy between amphetamines, physical activity, and environmental heat. Workers should not use illicit amphetamines to maintain alertness or enhance performance, especially when heat stress is present. Prevention of illicit amphetamine use is important, not only to avert hyperthermia but also to prevent other adverse effects. Workers should receive support for overcoming stimulant use disorders.§ Clinicians who prescribe amphetamines should consider obtaining an occupational history to facilitate discussions with patients about heat stress safety. Stakeholders should implement comprehensive occupational heat stress controls, such as those recommended by NIOSH (1) and OSHA (5), to prevent illnesses.
Corresponding author: Aaron W. Tustin, email@example.com, 202-693-2018.
1Directorate of Technical Support and Emergency Management, Occupational Safety and Health Administration, U.S. Department of Labor; 2Environmental and Occupational Health Sciences Institute, Rutgers University, Piscataway, New Jersey.
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
* The most common medically important amphetamine-class substances are amphetamine and its two enantiomers (levoamphetamine and dextroamphetamine), lisdexamfetamine, and methamphetamine.
† Florida, Kansas, Missouri, Nebraska, Ohio, Oklahoma, Rhode Island, and Texas.
- National Institute for Occupational Safety and Health. Criteria for a recommended standard: occupational exposure to heat and hot environments. Washington, DC: US Department of Health and Human Services, CDC, National Institute for Occupational Safety and Health; 2016. https://www.cdc.gov/niosh/docs/2016-106/pdfs/2016-106.pdfpdf icon
- Bowyer JF, Hanig JP. Amphetamine- and methamphetamine-induced hyperthermia: implications of the effects produced in brain vasculature and peripheral organs to forebrain neurotoxicity. Temperature (Austin) 2014;1:172–82. CrossRefexternal icon PubMedexternal icon
- Tustin AW, Cannon DL, Arbury SB, Thomas RJ, Hodgson MJ. Risk factors for heat-related illness in U.S. workers: an OSHA case series. J Occup Environ Med 2018;60:e383–9. CrossRefexternal icon PubMedexternal icon
- Darke S, Duflou J, Lappin J, Kaye S. Clinical and autopsy characteristics of fatal methamphetamine toxicity in Australia. J Forensic Sci 2018;63:1466–71. CrossRefexternal icon PubMedexternal icon
- Occupational Safety and Health Administration. Safety and health topics: heat. Washington, DC: US Department of Labor, Occupational Safety and Health Administration; 2019. https://www.osha.gov/SLTC/heatstress/external icon
Suggested citation for this article: Karasick AS, Thomas RJ, Cannon DL, et al. Notes from the Field: Amphetamine Use Among Workers with Severe Hyperthermia — Eight States, 2010–2019. MMWR Morb Mortal Wkly Rep 2020;69:1004–1005. DOI: http://dx.doi.org/10.15585/mmwr.mm6930a5external icon.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to firstname.lastname@example.org.